Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Goldman Sachs Emerging Companies Conference 2019
21 slides from Mayne Pharma's conference presentation, Apr 4, 2019
Slide 1: Mayne Pharma Group Limited – Goldman Sachs Emerging Companies Conference
For personal use only Mayne Pharma Group Limited Goldman Sachs Emerging Companies Conference April 2019 1
Slide 2: Disclaimer
Disclaimer For personal use only The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to invest
Slide 3: Group snapshot
Group snapshot For personal use only Mayne Pharma’s focus 1.2b doses sold A$530m revenue 70+ marketed in Australia and Affordable and in FY18 products US in 2018 effective medicines sourced and distributed efficiently Therapeutically focused expansion of product portfolio via R&D and business develo
Slide 4: Mayne Pharma's international footprint
Mayne Pharma’s international footprint For personal use only US Commercial Office Raleigh, North Carolina Product development and manufacturing facility, Australian Commercial Greenville, North Carolina 36.1 acre facility; 126,000ft2 of Office Melbourne, manufacturing space; 225,000ft2 total facilit
Slide 5: Operating platform transformed by M&A, R&D and other commercial initiatives
Mayne Pharma’s operating platform has been transformed by M&A, R&D and other commercial initiatives For personal use only Nov 2012 May 2015 Aug 2016 Aug 2016 Jul 2018 Oct 2018 M&A activity Acquisition of US$50m US$652m US$50m Acquisition of Acquisition of Metrics, Inc. for acquisition of acquisition
Slide 6: Mayne Pharma business units
Mayne Pharma business units US Business Units Rest of World For personal use only Generic Products Division Specialty Brands Division Metrics Contract Services Mayne Pharma (GPD) (SBD) (MCS) International (MPI) ● Develops, markets and ● Develops, markets and ● Provides contract ● Develops, markets a
Slide 7: Actively rebalancing the portfolio toward sustainable therapeutic areas and channels
Actively rebalancing the portfolio toward sustainable therapeutic areas and channels For personal use only 1H19 revenue by segment 1H19 revenue by category Generic Produ cts Division Dermatology 8% 19% 12% Specialty Brands Divis ion Women's Health 44% Infectious Disease A$274.4m Metrics Contract Ser
Slide 8: Understanding the US value chain
Understanding the US value chain… Generic industry – spread of $100 across value chain For personal use only Price concessions & Stocking Fees $8 $32 $36 Average Co-pay National Average Manufacturer Patient deductible Pharmacy Drug Acquisition Wholesaler Price (AMP) Cost (NADAC) Gx drug Plan manufac
Slide 9: Multi-channel strategy to drive growth
Multi-channel strategy to drive growth For personal use only Retail customer segmentation Channel consolidation / partnerships Estimated US generics market mix Other Wholesalers 10% 35% 23% Retailers 32% PBMs Insurer Secondary Specialty Major Retail / Retail / Government Wholesale channel pharmacy c
Slide 10: Channel strategy leveraging commercial infrastructure
Channel strategy built around leveraging commercial infrastructure to create a more seamless experience for key stakeholders For personal use only Patient Prescriber ü Convenience ü Reduced administration ü Right product ü Improved patient outcomes ü Price transparency Affordable ü Price certainty e
Slide 11: Unique and differentiated dermatology platform
Mayne Pharma has a unique and differentiated dermatology platform… For personal use only ● Mayne Pharma has a differentiated dermatology portfolio Mayne Pharma dermatology portfolio by key skin with an established front end commercial platform diseases - 4 patent protected dermatology brands and 5x
Slide 12: Two dermatology orphan disease programs in development
…with two dermatology orphan disease programs in development For personal use only SUBA®-itraconazole in BCCNS Trifarotene in rare skin diseases ● SUBA®-itraconazole is being repurposed as a ● Trifarotene is a new chemical entity under Phase II potential anti-cancer treatment in Basal Cell developme
Slide 13: Broad Women's Health portfolio covering physician needs
Broad Women’s Health portfolio covering physician needs For personal use only ● Mayne Pharma has an extensive women’s health Mayne Pharma contraceptive portfolio portfolio focused on contraceptives Market TRx1 Mayne Pharma’s marketed Type of contraceptive - 18 branded generic and 3 generic products
Slide 14: Launch of TOLSURA establishes new Infectious Disease / Pulmonology platform
Launch of TOLSURA™ establishes a new Infectious Disease / Pulmonology platform For personal use only ● Launch of TOLSURA™ (SUBA®-itraconazole) has enabled Potential expanded addressable market Mayne Pharma to establish a new infectious disease / pulmonology platform 11% Endemic mycoses, on label - T
Slide 15: New Gx competitive pressure on dofetilide, liothyronine and BAC capsule
New Gx competitive pressure on dofetilide, liothyronine and BAC capsule Leading edge For personal use only IQVIA product Change in product New Gx launches in product market Product market size # of Gx approvals TRx market share CY19 share (week ending (US$m) since 31 Dec 18 22 Mar 2019) Dofetilide c
Slide 16: Dermatology sales team driving prescription growth
Dermatology sales team driving prescription growth For personal use only Dermatology Weekly TRx (prescriptions) Average 1Q 1Q 1QCY19 v 9000 weekly TRx CY19 CY18 1QCY18 8000 DORYX® 4,024 4,390 (8%) franchise 7000 6000 FABIOR® 2,009 1,503 34% 5000 4000 SORILUX® 673 495 36% 3000 2000 LEXETTE™ 459 - - 1
Slide 17: DORYX remains a key specialty franchise
DORYX® remains a key specialty franchise For personal use only ● Mayne Pharma has retained 60% share of DORYX® franchise mix (prescriptions) doxycycline DR TRx 1% 120MG (DORYX MPC) ● DORYX® franchise continues to outperform from 7% 6% new formulations and favourable product sales mix 32% 200MG 50MG
Slide 18: LEXETTE launch gaining significant prescriber adoption
LEXETTE™ (halobetasol) launch gaining significant prescriber adoption For personal use only Comparison of LEXETTE™ and other recent branded halobetasol launches Weekly TRx (prescriptions) 900 800 700 600 500 400 300 200 100 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 LEXET
Slide 19: Development pipeline expected to drive future growth
Development pipeline expected to drive future growth For personal use only Select late stage pipeline projects Product / Mkt size No. Gx Formulation Pre- Indication Bx / Gx Phase II Phase III Filed FDA formulation (US$m)1 competitors development clinical SUBA®- BCCNS 300 Bx - itraconazole Congenital
Slide 20: Our key strategic priorities to drive sustainable future growth
Our key strategic priorities to drive sustainable future growth For personal use only Therapeutically High quality reliable Multi-channel, agile focused expansion supply commercial model of product portfolio § Developing and sourcing § Optimise manufacturing § Maximise value of products aligned to k
Slide 21: Keeping our promises to patients
Keeping our promises to patients, for better medicines and a better For personal use only tomorrow 21
Mayne Pharma Group — Goldman Sachs Emerging Companies Conference 2019 on 6ix